Search Results - "Sposini, Stefano"

Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients by Minutolo, Roberto, MD, PhD, Borzumati, Maurizio, MD, Sposini, Stefano, MD, Abaterusso, Cataldo, MD, Carraro, Gianni, MD, Santoboni, Alberto, MD, Mura, Carlo, MD, Filiberti, Oliviero, MD, Santoro, Domenico, MD, Musacchio, Romano, MD, Imperiali, Patrizio, MD, Fiorini, Fulvio, MD, De Nicola, Luca, MD, PhD, Russo, Domenico, MD

Get full text

Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients by Minutolo, Roberto, Bolasco, Piergiorgio, Chiodini, Paolo, Sposini, Stefano, Borzumati, Maurizio, Abaterusso, Cataldo, Mele, Alessandra A., Santoro, Domenico, Canale, Valeria, Santoboni, Alberto, Filiberti, Oliviero, Fiorini, Fulvio, Mura, Carlo, Imperiali, Patrizio, Borrelli, Silvio, Russo, Luigi, De Nicola, Luca, Russo, Domenico

“…Background In hemodialysis (HD), switching from erythropoiesis-stimulating agent (ESA) originators to biosimilars is associated with the need for doses…”
Get full text

Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients by Panichi, Vincenzo, Maggiore, Umberto, Taccola, Daniele, Migliori, Massimiliano, Rizza, Giovanni Manca, Consani, Cristina, Bertini, Alessio, Sposini, Stefano, Perez-Garcia, Rafael, Rindi, Paolo, Palla, Roberto, Tetta, Ciro

“…Background. Despite the well known association between interleukin-6 (IL-6) and cardiovascular mortality, no study has so far verified whether IL-6 adds…”
Get full text